Investigation of Therapeutic Ablation Versus Cardioversion for AF

NACompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

April 26, 2023

Study Completion Date

April 26, 2023

Conditions
Persistent Atrial FibrillationCardiac Arrhythmia
Interventions
PROCEDURE

DC Cardioversion

DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.

PROCEDURE

Pulmonary vein isolation

The cryoballoon (CE marked) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential freeze around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.

DEVICE

Implantable loop recorder

The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at the end of the procedure clinic by the electrophysiologist performing the procedure. The device will provide a continuous recording of the heart rhythm and rate, and will be able to down load duration of AF episodes via a home monitoring system to establish the primary endpoint of the study.

Trial Locations (1)

EC1 6BQ

Barts Health NHS Trust - St Bartholomew's Hospital and Whipps Cross Hospital, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Medtronic

INDUSTRY

lead

Barts & The London NHS Trust

OTHER

NCT03907982 - Investigation of Therapeutic Ablation Versus Cardioversion for AF | Biotech Hunter | Biotech Hunter